Lilly wins FDA approval for oral GLP-1 weight-loss pill

The FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 for adults with obesity or overweight, and Phase 3 results reported average weight loss of about 11–12% versus about 2% for placebo.

Federal regulators approved Foundayo (orforglipron), a once-daily oral GLP-1 treatment for adults with obesity or overweight with related conditions, the article reports. The article notes the pill can be taken without food or water restrictions, which the report contrasts with an oral semaglutide pill that requires dosing on an empty stomach. Phase 3 ATTAIN-1 trial results reported substantial average weight loss for patients on the highest dose compared with placebo over 72 weeks. The article also summarizes trial program size, cardiovascular risk marker findings, and initial distribution and pricing details. Reported details: - The FDA approved Foundayo (orforglipron) as a once-daily oral GLP-1 for adults with obesity or overweight with related conditions, according to the article. - In the Phase 3 ATTAIN-1 trial, patients on the highest dose lost an average of 27.3 pounds (12.4%) versus 2.2 pounds (0.9%) for placebo over 72 weeks; across participants the averages were about 25 pounds (11.1%) versus 5.3 pounds (2.1%) for placebo. - The article reports the broader ATTAIN program enrolled more than 4,500 patients globally and showed improvements in waist circumference, cholesterol, triglycerides, and blood pressure. - The article notes this oral pill can be taken without food or water restrictions, in contrast with an oral semaglutide product that requires empty-stomach dosing. - The article mentions Eli Lilly rose 4.15% intraday after the announcement. - The article reports Foundayo will be offered through LillyDirect with pricing listed as $25 per month for commercially insured patients, $149 for self-pay, and Medicare Part D pricing expected around $50 per month beginning July 2026. Summary: The approval introduces an oral GLP-1 option that the article says does not require food or water restrictions and that showed larger average weight loss than placebo in Phase 3 data. Foundayo is reported to be distributed initially through LillyDirect with stated pricing tiers, and Medicare Part D pricing is expected to take effect around July 2026.